DNAnexus completes $200 million new funding round

DNAnexus announced on Tuesday that it has completed a new funding round worth $200 million. Blackstone Growth led the round, with participation from early investors Northpond Ventures, GV, Perceptive Advisors, Innovatus Capital Partners, and Foresite Capital. Headquartered in Mountain View, California, DNAnexus specializes in bioinformatics analysis. This marks the company’s second major investment since its Series F round in 2019; it previously raised $100 million in 2020. DNAnexus stated that the new funds will be used to enhance its core genomics and multi-omics technology platforms, integrate new artificial intelligence and machine learning tools, and further expand internationally.

Worldview · New Perspectives: Investment Incentives for Biotechnology and Bio-based Industries in Malaysia

Amid the global wave of green transformation, Malaysia—leveraging its unique biodiversity resources, mature industrial policy framework, and innovative incentive mechanisms—has emerged as a hotspot for investment in biotechnology and bio-based industries. According to the latest data from the Malaysian Investment Development Authority (MIDA), approved investments in the biotechnology sector totaled over RM 1.12 billion between 2021 and 2024, generating more than 20,000 jobs. As the first Southeast Asian country to launch a national bioeconomy strategy, Malaysia has built an industry-wide incentive network through its ‘BioNexus’ certification scheme, green investment tax incentives, and multiple R&D subsidies—successfully attracting multinational enterprises such as Biocon and Topsoe to establish regional R&D centers and production facilities. This article provides an in-depth analysis of Malaysia’s biotechnology industry incentive policy framework, revealing how tax incentives, capital subsidies, and innovation ecosystem development jointly advance both economic growth and sustainable development. Strategic Policy Background: From Policy Pioneer to Global Benchmark Malaysia’s bioeconomy strategy originated with the 2005 National Biotechnology Policy and has since evolved through successive iterations—including the 2022 National Biofuel Policy and the Digital Economy Blueprint—to form a comprehensive policy chain spanning ‘R&D → commercialization → internationalization’. Dr. Yap of Taylor’s University notes that biotechnology is directly supporting Malaysia’s National Energy Transition Roadmap (NETR) carbon-reduction goals—aiming for net-zero greenhouse gas emissions by 2050—through bioenergy development, microbial fuel cells, and production of biodegradable materials. For instance, in the palm oil industry, gene-editing technologies have increased yields to 4.5 tons per hectare, while PME biodiesel meets EU CORSIA certification standards—bolstering export competitiveness while ensuring ecological compliance. I. Core Tax Incentive System: A Tiered Design—from Tax Holidays to Double Deductions 1. Statutory Income Tax Exemption: A Dynamic Tax Holiday Window For newly established biotech enterprises or expansion projects, Malaysia implements a tiered tax holiday policy. BioNexus-certified companies, for example, qualify for full exemption from statutory income tax for the first 10 years, followed by a reduced 20% rate for the subsequent 10 years. The duration of this exemption is dynamically adjusted based on investment scale, technological complexity, and industrial spillover effects. Biocon’s insulin manufacturing facility in Johor, which introduced nasal insulin delivery technology, not only secured a 10-year tax holiday but also earned an additional five years of tax relief due to its export contribution. MIDA data shows that qualified green-technology assets eligible between 2024 and 2026 may receive capital expenditure subsidies of up to 70%, creating a compound incentive effect combining tax exemption and subsidy. 2. Green Investment Tax Allowance (GITA): Targeted Green-Capital Subsidies Under the Green Technology Tax Incentive Guidelines, enterprises may claim a 70% GITA subsidy on qualifying capital expenditures incurred for in-house green technology assets during 2024–2026. This policy directly stimulates investment in renewable energy equipment, energy-efficient production systems, and carbon capture technologies. For example, Topsoe’s Sustainable Aviation Fuel (SAF) project—developed in partnership with Fathopes Energy—uses HydroFlex™ hydrotreating technology to process waste cooking oil. The project not only received GITA support but also became the first SAF production facility in Southeast Asia certified under the International Sustainability and Carbon Certification (ISCC) system, thanks to its compliance with EU ReFuelEU standards. With an annual processing capacity of 200,000 tons, the facility reduces CO₂-equivalent emissions by 500,000 tons per year.

BioNexus Launches New Corporate Website with Expanded Business and Investor Resources

22 hours ago

BioNexus Gene Lab Corp unveiled a redesigned website detailing its RNA screening, chemical business, and healthcare investments to improve investor access and reporting clarity.

The Manila Times

2026-02-23

BioNexus Gene Lab Corp. Completes Chemrex Governance Restructuring; Appoints Matthew Barsing as Chairman

2026-03-12

BioNexus Gene Lab Corp. Appoints Dr. Muthu Meyyappan as CCO of Fidelion Diagnostics to Lead VitaGuard™ MRD Commercialization

2026-04-04

BioNexus Gene Lab Corp Stock Drops 3% on Poor Ratings

2026-04-14

BioNexus Gene Lab 10-K: Revenue $7.42M, EPS $(1.61)

2026-05-15

BioNexus Gene Lab Corp Q1 2026 Earnings: Revenue $22.84K, EPS ($0.23)